Coral Reefs In The Philippines,
2020
American University Washington College of Law
Coral Reefs In The Philippines, Maggie Parks
Sustainable Development Law & Policy
No abstract provided.
Practitioner's Corner: Ken Markowitz On Serving As An Environmental Advocate,
2020
American University Washington College of Law
Practitioner's Corner: Ken Markowitz On Serving As An Environmental Advocate, Kimberly Righter
Sustainable Development Law & Policy
No abstract provided.
2001 Supreme Court Redux,
2020
American University Washington College of Law
2001 Supreme Court Redux, Mary Stevens
Sustainable Development Law & Policy
No abstract provided.
Next Verse, Same As The First: Inadequacies In The Government's Legal Approach Toward Biotechnology,
2020
American University Washington College of Law
Next Verse, Same As The First: Inadequacies In The Government's Legal Approach Toward Biotechnology, Kimberly Righter
Sustainable Development Law & Policy
No abstract provided.
Implementing Kyoto,
2020
Center for International Environmental Law
Implementing Kyoto, Glenn Wiser
Sustainable Development Law & Policy
No abstract provided.
Regulating Medicines In A Globalized World With Increased Recognition And Reliance Among Regulators: A National Academies Report,
2020
Georgetown University - Law Center - O'Neill Institute for National and Global Health Law
Regulating Medicines In A Globalized World With Increased Recognition And Reliance Among Regulators: A National Academies Report, Lawrence O. Gostin, Alastair J. Wood, Patricia A. Cuff
Georgetown Law Faculty Publications and Other Works
Research and development of pharmaceuticals are now complex global endeavors, with drug companies operating worldwide using global supply chains. Pharmaceutical companies source their products from many countries, conduct trials in multiple sites, and market essential drugs and vaccines globally. Yet oversight of drug safety and effectiveness is primarily the responsibility of national regulators of variable capacities. National agencies often undertake product reviews without recognizing that similar reviews are occurring elsewhere, sometimes simultaneously. The result is duplication and redundancy, which benefits neither national nor global public health. Supported by the US Food and Drug Administration (FDA), the National Academies of Sciences, …
The Doctrine Of Wilful Blindness In Drug Offences: Adili Chibuike Ejike V Public Prosecutor [2019] 2 Slr 254,
2020
Singapore Management University
The Doctrine Of Wilful Blindness In Drug Offences: Adili Chibuike Ejike V Public Prosecutor [2019] 2 Slr 254, Rennie Whang
Research Collection Yong Pung How School Of Law
In Adili Chibuike Ejike v Public Prosecutor [2019] 2 SLR 254, the Court of Appeal clarified the operation of the wilful blindness doctrine in the context of knowing possession for drug offences. In particular, it affirmed wilful blindness as a doctrine of substantive rather than evidential law, which applies as a limited extension to the legal requirement of actual knowledge. The court then articulated a three-part test for the finding of wilful blindness in relation to knowledge as an ingredient of possession. However, it left open the content of the doctrine as applied to the element of knowledge in drug …
The Cost Of Novelty,
2020
University of Michigan Law School
The Cost Of Novelty, Will Nicholson Price Ii
Articles
Patent law tries to spur the development of new and better innovative technology. But it focuses much more on “new” than “better”—and it turns out that “new” carries real social costs. I argue that patent law promotes innovation that diverges from existing technology, either a little (what I call “differentiating innovation”) or a lot (“exploring innovation”), at the expense of innovation that tells us more about existing technology (“deepening innovation”). Patent law’s focus on newness is unsurprising, and fits within a well-told narrative of innovative diversity accompanied by market selection of the best technologies. Unfortunately, innovative diversity brings not only …
The Ip Of Ipas,
2020
University of Georgia School of Law
The Ip Of Ipas, Stephen Wolfson, Brian Roth, Chase Scott, Dustin Watts, Charles Hicks, Shivani Patel
Other Colloquium, Conferences, and Symposia
Hosted by the Journal of Intellectual Property Law, this panel brought Brian Roth (Southern Brewing Co.), Chase Scott (Taylor, Feil, Harper & Lumsden, P.C.), and Dustin Watts (Terrapin Beer Co.) together with Stephen Wolfson (Research & Copyright Services Librarian, UGA Law School) and students from the Journal of Intellectual Property Law to discuss how breweries are navigating intellectual property issues. Free koozies to commemorate the event were distributed.
Voluntary Licensing Of Pharmaceuticals: The Strategy Against Compulsory Licensing,
2020
American University Washington College of Law
Voluntary Licensing Of Pharmaceuticals: The Strategy Against Compulsory Licensing, Daniel D. Kim
Intellectual Property Brief
No abstract provided.
Non-Transparent Pbm Cash Flows: Balancing Market Forces Under A Reluctant Legislative Regime,
2020
William & Mary Law School
Non-Transparent Pbm Cash Flows: Balancing Market Forces Under A Reluctant Legislative Regime, John Mcguinness
William & Mary Business Law Review
No abstract provided.
Going Hemp Wild: Understanding The Challenges And Opportunities For Fda Regulation Of Cbd In Food Products,
2020
University of Arkansas, Fayetteville
Going Hemp Wild: Understanding The Challenges And Opportunities For Fda Regulation Of Cbd In Food Products, Hannah Catt
Journal of Food Law & Policy
After the passage of the 2018 Farm Bill, champions of hemp began to tout opportunities for farmers and businesses involved with the crop. The industry has rallied around one of hemp’s major byproducts, cannabidiol, or CBD. However, the demand for CBD has left the Food and Drug Administration (“FDA”) playing catch-up. This article explains what CBD is, how it is derived, current FDA-approved uses, and a current path forward for the FDA in creating guidance for industry and consumers.
Updating The Building Code To Include Indoor Farming Operations,
2020
University of Arkansas, Fayetteville
Updating The Building Code To Include Indoor Farming Operations, Clint Simpson
Journal of Food Law & Policy
Urban agricultural production has grown to be a critical tool in the battles for food security and sustainability. A common regulatory barrier to urban agricultural operations big and small has been ambiguity in land-use laws. Local governments are increasingly friendly toward community gardens, small greenhouse farming operations, farmers markets, and the like. Many have sought to lift regulatory restrictions and provide clarity in the law. However, while these efforts benefit a multitude of local food production efforts, they do little to address the regulatory ambiguities faced by commercial-scale, indoor farming operations, especially vertical farms. Particularly concerning to indoor vertical farms …
School Of Law Faculty And Professional Staff,
2020
University of Arkansas, Fayetteville
School Of Law Faculty And Professional Staff, Journal Editors
Journal of Food Law & Policy
No abstract provided.
Editorial Board,
2020
University of Arkansas, Fayetteville
Contents,
2020
University of Arkansas, Fayetteville
Journal Of Food Law & Policy - Fall 2019,
2020
University of Arkansas, Fayetteville
Journal Of Food Law & Policy - Fall 2019, Journal Editors
Journal of Food Law & Policy
No abstract provided.
Fighting America’S Best-Selling Product: An Analysis Of And Solution To The Opioid Crisis,
2020
Washington and Lee University School of Law
Fighting America’S Best-Selling Product: An Analysis Of And Solution To The Opioid Crisis, Ashley Duckworth
Washington and Lee Journal of Civil Rights and Social Justice
Deaths from drug overdoses have doubled over the last ten years and are now the leading cause of accidental death in the United States. Although some overdoses may have involved more than one drug, prescription and/or illicit opioids were involved in many of these drug overdose fatalities. The Food and Drug Administration (FDA), Center for Disease Control and Prevention (CDC), and Congress have enacted a string of regulations, statutes, and programs since the early 1990s, but nothing has seriously improved the opioid epidemic as it stands. If anything, the use of opioids has persisted. Many people want pharmaceutical companies to …
Why The Dea & Not The Fda? Revisiting The Regulation Of Potentially Addictive Substances,
2020
Florida International University College of Law
Why The Dea & Not The Fda? Revisiting The Regulation Of Potentially Addictive Substances, Taleed El-Sabawi
Faculty Publications
In addressing the opioid overdose crisis, Congress has explicitly questioned its historic reliance on a criminal justice approach to problem drug use and has instead adopted a more health-oriented approach. Despite Congress' rhetoric, the DEA, a criminal justice agency, continues to retain the power to make key decisions on the classification of potentially-addictive substances, thereby affecting their manufacture, distribution, and overall availability. While the DEA is statutorily required to defer to the Food and Drug Administration (“FDA”), a public health agency, at junctions of the decision-making process, the current “split enforcement” scheme laid out in the statutes has not actualized …
(Almost) No Bad Drugs: Near-Total Products Liability Immunity For Pharmaceuticals Explained,
2020
Brooklyn Law School
(Almost) No Bad Drugs: Near-Total Products Liability Immunity For Pharmaceuticals Explained, Anita Bernstein
Faculty Scholarship
No abstract provided.
